UK markets closed

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.82-0.25 (-4.12%)
At close: 06:59PM BST

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340

Full-time employees68

Key executives

NameTitlePayExercisedYear born
Mr. Conley CheeCEO, President & Director672.24kN/A1970
Dr. Richard A. Young Ph.D.Scientific Founder, Member of Scientific Advisory Board & Director51.75kN/A1954
Mr. Jason HaasChief Financial Officer672.22kN/A1968
Dr. David A. Roth M.D.Chief Medical Officer715.73kN/A1963
Dr. James E. Bradner M.D.FounderN/AN/A1972
Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Ms. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsN/AN/AN/A
Mr. Gerald E. Quirk Esq., J.D.Chief Legal & Compliance Officer and Chief Business Officer127.07kN/A1968
Ms. Lisa RobertsVice President of Human ResourcesN/AN/AN/A
Ms. Kristin StephensChief Development OfficerN/AN/A1973
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Syros Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2024 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.